New study shows intermittent HT as effective as continuous HT

vartabebo

This report was apparently published today at the annual meeting of the American Society of Clinical Oncology...

http://www.medicalnewstoday.com/releases/227668.php

VascodaGama

NCCN may alter their guidelines
Arthur

Great news. These findings will influence the importance given to the newer drugs as well (such as Abiraterone acetate), which do not make part of the protocols of the patients/cases used in the trials but have proven effectiveness with lesser side effects.
I hope institutions like NCCN will alter their guidelines and introduce newer measures regarding HT, based on truthful results like these.

Here is the abstract of the trials;
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=77775

Thanks for posting the article.

VG